Washington, DC – October 7, 2016 – Cooley advised the underwriters on Catabasis Pharmaceuticals’ $11.5 million underwritten registered offering.
Cowen and Company acted as sole book-running manager for the offering.
Catabasis, which trades on The NASDAQ Global Market, is a clinical-stage biopharmaceutical company focused on the discovery and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted (SMART) linker technology platform. Catabasis's SMART linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease.
Cooley advised the underwriters on Catabasis’s $69 million initial public offering in 2015.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.